Two Targets, One Hit: New Anticancer Therapeutics To Prevent Tumorigenesis Without Cardiotoxicity
FRONTIERS IN PHARMACOLOGY(2021)
摘要
A serious adverse effect of cancer therapies is cardiovascular toxicity, which significantly limits the widespread use of antineoplastic agents. The promising new field of cardio-oncology offers the identification of potent anti-cancer therapeutics that effectively inhibit cancer cell proliferation without causing cardiotoxicity. Future introduction of recently identified cardio-safe compounds into clinical practice (including ERK dimerization inhibitors or BAX allosteric inhibitors) is expected to help oncologists avoid unwanted cardiological complications associated with therapeutic interventions.
更多查看译文
关键词
MAPK, ERK pathway, bax, cancer therapy, clinical trial, cardiotoxicity
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要